TanCAR7

TanCAR7 is an investigational **tandem chimeric antigen receptor (CAR) T-cell therapy** that targets both **CD19 and CD20 antigens** on B cells. These engineered T cells are designed to address antigen escape and resistance associated with CAR T-cell therapies that target only a single antigen. By simultaneously targeting **CD19 and CD20**, TanCAR7 T cells aim to reduce relapse due to single-antigen loss and enhance tumor cell killing. In clinical studies, TanCAR7 has shown robust and durable antitumor effects, with a safety profile that includes cytokine release syndrome (CRS) but low rates of severe neurotoxicity. The therapy is primarily developed for patients with **relapsed or refractory non-Hodgkin lymphoma**, including aggressive subtypes such as diffuse large B-cell lymphoma. Studies in China, including phase 1 and 2 trials, have reported high response rates, promising progression-free survival, and manageable toxicity[1][2][3][6][7].

Other names

TanCAR7TanCAR-7TanCAR 7